Local imbalance of proangiogenic and antiangiogenic factors: A potential mechanism of focal necrosis and dormancy in tumors

Cancer Research

Volumn 60, Issue 5, 2000, Pages 1442-1448

  Ramanujan, Saroja ^a   Koenig, Gerald C ^a   Padera, Timothy P ^a   Stoll, Brian R ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; GROWTH FACTOR; GROWTH INHIBITOR;

ANGIOGENESIS; ARTICLE; CANCER INVASION; HALF LIFE TIME; MATHEMATICAL ANALYSIS; MODEL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; SOLID TUMOR;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; HUMANS; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NECROSIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0034161885     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Folkman, J. Tumor angiogenesis. In: P. M. Mendelsohn, M. A. P. Howley, and L. A. Liotta (eds.), The Molecular Basis of Cancer, pp. 206-232. Philadelphia: W. B. Saunders, 1995.
2. Harach, H. R., Franssila, K. O., and Wasenius, V. M. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer (Phila.), 56: 531-538, 1985.
3. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
4. Szabo, S., and Sandor, Z. The diagnostic and prognostic value of tumor angiogenesis. Eur. J. Surg., 582 (Suppl.): 99-103, 1998.
5. Jain, R. K., Koenig, G. C., Dellian, M., Fukumura, D., Munn, L. L., and Melder, R. J. Leukocyte-endothelial adhesion and angiogenesis in tumors. Cancer Metastasis Rev., 15: 195-204, 1996.
6. Freeman, M. R., Schneck, F. X., Gagnon, M. L., Corless, C., Soker, S., Niknejad, K., Peoples, G. E., and Klagsbrun, M. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res., 55: 4140-4145, 1995.
7. Hlatky, L., Tsionou, C., Hahnfeldt, P., and Coleman, C. N. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res., 54: 6083-6086, 1994.
8. Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E. C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., and Seed, B. Tumor induction of VEGF promoter activity in stromal cells. Cell, 94: 715-725, 1998.
9. Ferrara, N., and Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev., 18: 4-25, 1997.
10. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Physiol., 146: 1029-1039, 1995.
11. Christofori, G. The role of fibroblast growth factors in tumour progression and angiogenesis. In: R. Bicknell, C. E. Lewis, and N. Ferrara (eds.), Tumour Angiogenesis, pp. 201-238. Oxford: Oxford University Press, 1997.
12. Rastinejad, F., Polverini, P. J., and Bouck, N. P. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell, 56: 345-355, 1989.
13. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin. A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
14. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin. An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
15. Sugarbaker, E. V., Thornthwaite, J., and Ketcham, A. Inhibitory effect of a primary tumor on metastasis. In: S. B. Day, W. P. L. Myers, P. Stansly, S. Garrattini, and M. G. Lewis (eds.), Progress in Cancer Research and Therapy, pp. 227-240. New York: Raven Press, 1977.
16. Holmgren, L., O'Reilly, M. S., and Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1: 149-153, 1995.
17. Griffon-Etienne, G., Boucher, Y., Brekken, C. Suit, H. D., and Jain, R. K. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res., 59: 3778-3782, 1999.
18. Jain, R. K. Determinants of tumor blood flow: a review. Cancer Res., 48: 2641-2658, 1988.
19. Jain, R. K., and Wei, J. Dynamics of drug transport in solid tumors: distributed parameter model. J. Bioeng., 1: 313-329, 1977.
20. Bird, R. B., Stewart, W. E., and Lightfoot, E. N. Transport Phenomena. New York: John Wiley & Sons, Inc., 1960.
21. Deen, W. M. Analysis of Transport Phenomena. Oxford University Press, 1998.
22. Nugent, L. J., and Jain, R. K. Extravascular diffusion in normal and neoplastic tissues. Cancer Res., 44: 238-244, 1984.
23. Chary, S. R., and Jain, R. K. Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. Proc. Natl. Acad. Sci. USA, 86: 5385-5389, 1989.
24. Endrich, B., Reinhold, H. S., Gross, J. F., and Intaglietta, M. Tissue perfusion inhomogeneity during early tumor growth in rats. J. Natl. Cancer Inst., 62: 387-395, 1979.
25. Tannock, I. F. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br. J. Cancer, 22: 258-273, 1968.
26. Vaupel, P. Hypoxia in neoplastic tissue. Microvasc. Res., 13: 399-408, 1977.
27. Franko, A. J., and Sutherland, R. M. Oxygen diffusion distance and development of necrosis in multicell spheroids. Radiat. Res., 79: 439-453, 1979.
28. Hilmas, D. E., and Gillette, E. L. Morphometric analyses of the microvasculature of tumors during growth and after X-irradiation. Cancer (Phila.), 33: 103-110, 1974.
29. Sckell, A., Safabakhsh, N., Dellian, M., and Jain, R. K. Primary tumor size-dependent inhibition of angiogenesis at a secondary site: an intravital microscopic study in mice. Cancer Res., 58: 5866-5869, 1998.
30. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
31. Edelman, E. R., Nugent, M. A., and Karnovsky, M. J. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc. Natl. Acad. Sci. USA, 90: 1513-1517, 1993.
32. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
33. Takei, Y., Kurobe, M., Uchida, A., and Hayashi, K. Serum concentrations of basic fibroblast growth factor in breast cancer. Clin. Chem., 40: 1980-1981, 1994.
34. Morelli, D., Lazzerini, D., Cazzaniga, S., Squicciarini, P., Bignami, P., Maier, J. A., Sfondrini, L., Menard, S., Colnaghi, M. I., and Balsari, A. Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers. Clin. Cancer Res., 4: 1221-1225, 1998.
35. Dawes, J., Clemetson, K. J., Gogstad, G. O., McGregor, J., Clezardin, P., Prowse, C. V., and Pepper, D. S. A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, β-thromboglobulin and platelet factor 4 in healthy volunteers. Thromb. Res., 29: 569-581, 1983.
36. Prehn, R. T. Two competing influences that may explain concomitant tumor resistance. Cancer Res., 53: 3266-3269, 1993.
37. Prehn, R. T. The inhibition of tumor growth by tumor mass. Cancer Res., 51: 2-4, 1991.
38. Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J., and Jain, R. K. Solid stress inhibits the growth of multicellular tumor spheroids. Nat. Biotechnol., 15: 778-783, 1997.
39. Berk, D. A., Yuan, F., Leunig, M., and Jain, R. K. Direct in vivo measurement of targeted binding in a human tumor xenograft. Proc. Natl. Acad. Sci. USA, 94: 1785-1790, 1997.
40. Clezardin, P., Frappart, L., Clerget, M., Pechoux, C., and Dlemas, P. D. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res., 53: 1421-1430, 1993.
41. Mayr, N. A., J. J., S., Robinson, R. A., Vanmetre, J. E., and Hussey, D. H. Morphometric studies in intraductal breast carcinoma using computerized image analysis. Cancer (Phila.), 67: 2805-2812, 1991.
42. Lyng, H., Skretting, A., and Rofstad, E. K. Blood flow in six human melanoma xenograft lines with different growth characteristics. Cancer Res., 52: 584-592, 1992.
43. Groebe, K., and Mueller-Klieser, W. On the relation between size of necrosis and diameter of tumor spheroids. Int. J. Radiat. Oncol. Biol. Phys., 34: 395-401, 1996.
44. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond.), 359: 843-845, 1992.
45. Demicheli, R., Teenziani, M., Valagussa, P., Moliterni, A., Zambetti, M., and Bonadonna, G. Local recurrences following mastectomy: support for the concept of tumor dormancy. J. Natl. Cancer Inst., 86: 45-48, 1994.
46. Demicheli, R., Abbattista, A., Miceli, R., Valagussa, P., and Bonadonna, G. Time distribution of the recurrence of risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res. Treat., 41: 177-185, 1996.
47. Barnhill, R. L., Piepkorn, M. W., Cochran, A. J., Flynn, E., Karaoli, T., and Folkman, J. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. Arch. Dermatol., 134: 991-994, 1998.
48. Hahnfeldt, P. P. D., Folkman, J., and Hlatky, L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res., 59: 4770-4775, 1999.
49. Nelson, N. J. Angiogenesis research is on fast forward. J. Natl. Cancer Inst., 91: 820-822, 1999.
50. Zetter, B. R. Angiogenesis and tumor metastasis. Annu. Rev. Med., 49: 407-424, 1998.
51. Rak, J., and Kerbel, R. S. Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Nat. Med., 15: 231-236, 1996.
52. Fidler, I. J., and Ellis, L. M. The implications of angiogenesis for biology and therapy of cancer metastasis. Cell, 79: 185-188, 1994.
53. Jain, R. K. 1996 Landis Award Lecture: delivery of molecular and cellular medicine to solid tumors. Microcirculation, 4: 1-23, 1997.
54. Dvorak, H. F. Tumors. Wounds that do not heal. N. Engl. J. Med., 315: 1650-1659. 1986.
55. Damon, D. H., Lobb, R. R., D'Amore, P. A., and Wagner, J. A. Heparin potentiates the action of acidic fibroblast growth factor by prolonging its biological half-life. J. Cell. Physiol., 138: 221-226, 1989.
56. Yamamoto, Y., Toi, M., Kondo, S., Matsumoto, T., Suzuki, H., Kitamura, M., Tsuruta, K., Taniguchi, T., Okamoto, A., Mori, T., Yoshida, M., Ikeda, T., and Tominaga, T. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin. Cancer Res., 2: 821-826, 1996.
57. Trzeciak, M. C., McGregor, J., Renaux, J. L., Ville, D., Berruyer, M., Dawes, J., and Dechavanne, M. Plasma thrombospondin in patients with chronic renal failure, liver disease and splenectomy. Thromb. Res., 40: 121-128, 1985.
58. Sasaki, T., Fukai, N., Mann, K., Gohring, W., Olsen, B. R., and Timpl, R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J., 17: 4249-4256, 1998.